Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1674-1676

  Tirado, Carlos A ^a   Chen, Weina ^a   Huang, Lily Jun shen ^a   Laborde, Carrie ^a   Hiemenz, Matthew C ^a   Valdez, Federico ^a   Ho, Kevin ^a   Winick, Naomi ^a   Lou, Zhenjun ^a   Koduru, Prasad ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

B lymphoblastic leukemia; JAK2 rearrangement; T(9 ; 22)(p24 ; q11.2)

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; CLOFARABINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; JANUS KINASE 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOBLAST; CASE REPORT; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; DISEASE COURSE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HLA MATCHING; HUMAN; HUMAN CELL; HYPERLEUKOCYTOSIS; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; LEUKEMOGENESIS; LEUKOCYTOSIS; MALE; MOLECULAR PROBE; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; HUMANS; JANUS KINASE 2; LEUKEMIA, B-CELL; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSLOCATION, GENETIC;

EID: 78149358109     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.05.031     Document Type: Article

References (10)

1. Smith C.A., Fan G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol 2008, 39:795-810.
2. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
3. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
4. Mullighan C.G., Zhang J., Harvey R.C., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009, 106:9414-9418.
5. Lacronique V., Boureux A., Valle V.D., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309-1312.
6. Peeters P., Raynaud S.D., Cools J., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90:2535-2540.
7. Reiter A., Walz C., Watmore A., et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005, 65:2662-2667.
8. Poitras J.L., Dal Cin P., Aster J.C., et al. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 2008, 47:884-889.
9. Nebral K., Denk D., Attarbaschi A., et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009, 23:134-143.
10. Patnaik M.M., Knudson R.A., Gangat N., et al. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. Eur J Haematol 2010, March:1-7. [Epub ahead of print].